Share the post "Lincoln Pharmaceuticals announced Financial Results Q1 2024"
Highlights
- The presented financial data is Consolidated to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 8.6 % in the past year, substantial increase in net sales/revenue by 3.36 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 35.34 %. Marginal increase in other income during this quarter, up by 48.3%.
- Profit over the Year and quarter: Significant improvement in profitability for Lincoln Pharmaceuticals Limited. Notable increase of 24.5 % in net profit Year to Year, Lincoln Pharmaceuticals Limited’s profitability increased by 27.29 % in this quarter.
- EPS over the Year and quarter: EPS increased by 24.55 % Year to Year. EPS increased by 27.37 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 135.62 Cr | Rs. 142.493 Cr | Rs. 147.282 Cr | + 3.36 % | + 8.6 % |
| Expenses | Rs. 114.9 Cr | Rs. 124.11 Cr | Rs. 124.55 Cr | + 0.35 % | + 8.4 % |
| Operating Profit | Rs. 20.72 Cr | Rs. 18.38 Cr | Rs. 22.73 Cr | + 23.67 % | + 9.7 % |
| OPM % | 15.28 % | 12.9 % | 15.43 % | + 2.53 % | + 0.15 % |
| Other Income | Rs. 7.691 Cr | Rs. 7.019 Cr | Rs. 10.409 Cr | + 48.3 % | + 35.34 % |
| Interest | Rs. 0.42 Cr | Rs. 0.5 Cr | Rs. 0.44 Cr | -12 % | + 4.76 % |
| Depreciation | Rs. 2.55 Cr | Rs. 2.69 Cr | Rs. 3.22 Cr | + 19.7 % | + 26.27 % |
| Profit before tax | Rs. 25.44 Cr | Rs. 22.21 Cr | Rs. 29.48 Cr | + 32.73 % | + 15.88 % |
| Tax % | 25.28 % | 16.29 % | 19.7 % | + 3.41 % | -5.58 % |
| Net Profit | Rs. 19.01 Cr | Rs. 18.6 Cr | Rs. 23.67 Cr | + 27.26 % | + 24.51 % |
| EPS in Rs | Rs. 9.49 | Rs. 9.28 | Rs. 11.82 | + 27.37 % | + 24.55 % |
Today, we’re looking at Lincoln Pharmaceuticals Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 8.6 %. However, it did see a marginal increase of 3.36 % from the previous quarter. Expenses ticked up slightly by 0.35 % quarter-on-quarter, aligning with the annual rise of 8.4 %. Operating profit, while up 9.7 % compared to last year, faced a quarter-on-quarter increase of 23.67 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.15 %, but an expansion of 2.53 % sequentially. Other income rose by 48.3 % compared to the last quarter, despite an annual growth of 35.34 %. Interest expenses dropped significantly by -12 % from the previous quarter, yet the year-over-year increase remains at a moderate 4.76 %. Depreciation costs climbed by 19.7 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 26.27 %. Profit before tax grew annually by 15.88 % but saw an increase from the preceding quarter by 32.73 %.
Tax expenses as a percentage of profits decreased slightly by -5.58 % compared to last year, with a more notable quarter-on-quarter increase of 3.41 %. Net profit rose by 24.51 % year-on-year but experienced a 27.26 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 24.55 % but a quarterly rise of 27.37 %. In summary, Lincoln Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 135.62 Cr | Rs. 142.493 Cr | Rs. 147.282 Cr | + 3.36 % | + 8.6 % |
| Expenses | Rs. 114.9 Cr | Rs. 124.11 Cr | Rs. 124.55 Cr | + 0.35 % | + 8.4 % |
| Operating Profit | Rs. 20.72 Cr | Rs. 18.38 Cr | Rs. 22.73 Cr | + 23.67 % | + 9.7 % |
| Net Profit | Rs. 19.01 Cr | Rs. 18.6 Cr | Rs. 23.67 Cr | + 27.26 % | + 24.51 % |
| EPS in Rs | Rs. 9.49 | Rs. 9.28 | Rs. 11.82 | + 27.37 % | + 24.55 % |
In reviewing Lincoln Pharmaceuticals Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 8.6 % year-on-year growth, however, there was a minor increase of 3.36 % from the previous quarter. Expenses rose by 8.4 % compared to the previous year, with a 0.35 % increase quarter-on-quarter. Operating Profit surged by 9.7 % annually, and saw a 23.67 % increase from the last quarter.
Net Profit showed yearly increase of 24.51 %, and experienced a 27.26 % increase from the previous quarter. Earnings Per Share (EPS) rose by 24.55 % annually, however rose by 27.37 % compared to the last quarter. In essence, while Lincoln Pharmaceuticals Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
[my_shortcode1 values=”Lincoln Pharmaceuticals “]
